

People

Joe Donahue appointed President of LION

LION Bioscience (<http://www.lionbioscience.com>) has announced the appointment of Joseph F. Donahue as President, where he will lead LION's North American operations and provide guidance to the company's worldwide sales and business operations.

Daniel Keesman, LION's Chief Business Officer, said: 'Joe has an almost 20-year record of demonstrated success in quality organizations. His global sales and marketing experience and his strong leadership and management skills will contribute tremendously as we grow our business.'

Donahue joins LION from Spotfire, where he most recently served as Vice President of Global Life Sciences and Chemical Markets. Prior to joining Spotfire, he was VP of North American Sales at MDL Information Systems.

Friedrich von Bohlen, Founder and CEO of LION, said: 'Joe's expertise in life sciences, his ability to focus organizations... and his ability to establish mutually beneficial strategic partnerships will help LION speed up the delivery of solutions that help companies address some of the most pressing challenges they are facing in life sciences R&D.'

Robert H. Zaugg appointed CEO of OPTIME Therapeutics

OPTIME Therapeutics (<http://www.optimeinc.com>) recently announced the appointment of Robert H. Zaugg as its President and Chief Executive Officer. He will lead OPTIME in its mission to rapidly develop and commercialize novel, topically administered therapeutic products.

Brian K. Campion, OPTIME's Director of Corporate Development commented: 'Bob's proven business development background and commercial focus will be invaluable now that OPTIME is actively pursuing strategic alliances for our innovative therapies, including our lead product Liposome Encapsulated Diclofenac Analgesic (LEDA).'

Zaugg joins OPTIME with 20 years of experience as an entrepreneurial scientist and business executive in the

biopharmaceutical industry. He has initiated, negotiated and closed numerous strategic alliances with an aggregate value exceeding US\$500 million, including deals with Merck, Pfizer, Human Genome Sciences, Aventis, Baxter, Boston Scientific, Centocor and Genzyme.

Following his appointment, Zaugg stated: 'This is an exceptional opportunity to lead a company with a unique and powerful technology that facilitates the efficient and rapid development of novel, topical pharmaceutical products.'

Anil Singhal joins Xerion Pharmaceuticals

Xerion Pharmaceuticals (<http://www.xerion-pharma.com>) have announced the appointment of Anil Singhal to the post of Chief Drug Development Officer. He will be based in Cambridge, MA, USA, and will be responsible for the implementation of all aspects of the Company's pre-clinical and clinical programs for the development of therapeutics for cancer and cardiovascular disease.

Markus Ewert, Xerion's CEO commented: 'It is of utmost strategic importance that we establish a solid drug development expertise, and Anil is the perfect match to head our drug development activities.'

Singhal was previously Vice President at Light Sciences Corp. and Pacific Pharmaceuticals, where he led various oncology programs through pre-clinical and clinical stages of development. On his appointment, Singhal said: 'I am delighted to join the highly motivated Xerion team at this challenging stage. This gives me the opportunity to fully contribute my experience and knowledge to further develop therapeutic products from the multiple promising targets that have already been identified and characterized by Xerion'.

CancerVax appoints Martin Mattingly as Executive Vice President of marketing and business development

CancerVax Corporation (<http://www.cancervax.com>) has announced that Martin Mattingly has been appointed to the position of Executive Vice President

and will oversee corporate development and marketing for the company.

President and CEO of CancerVax, David F. Hale, commented: 'The addition of Martin to our executive team comes at a key time as we continue to advance the CANVAXIN™ therapeutic cancer vaccine through Phase III clinical trials for the treatment of metastatic melanoma and prepare to begin additional trials for the treatment of colon cancer.'

Mattingly previously served as Vice President, Product Development Group for Pfizer and Vice President of Global Marketing, Senior Director of Marketing and Director of Product Marketing for Agouron. Mattingly has also held Senior Marketing Positions at Eli Lilly and Co. where he was involved in oncology and CNS marketing, including the launch of Gemzar® and programs for new Prozac® indications.

Phoqus Pharmaceuticals appoints Andy Jones as CEO

Phoqus Pharmaceuticals (<http://www.phoqus.com>) has appointed Andy Jones as CEO, to continue to steer the company in its aggressive development drive. The new appointment follows a successful year in which the company has completed its third funding round of £7 million from its existing investors and the expansion of its pilot manufacturing plant to meet global demand for its products.

Formerly Vice President, Andy replaced Frank Armstrong on 1st May 2003. He has been with the company for one year and prior to his appointment at Phoqus, held senior leadership positions at AstraZeneca and ICI.

Commenting upon his appointment he said: 'Together we will ensure that Phoqus achieves its full year goals for 2003, and delivers the exciting potential that Phoqus represents for its investors, its employees and for our customers.'

Phoqus, based in Kent, UK, has developed a range of unique oral drug delivery systems based on the principles of electrostatic deposition technology that are used in photocopying.

People was written by
Steve Carney